Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hucMSC-derived exosomes (HucMSC-Exos) are extracellular vesicles, typically ranging from 30 to 150 nm in diameter, secreted by human umbilical cord mesenchymal stem cells (hucMSCs). These vesicles serve as a biologic therapeutic modality that facilitates intercellular communication by delivering a complex cargo of proteins (such as insulin and superoxide dismutase 1), mRNAs, and microRNAs (notably miR-133b) to recipient cells. In the context of Parkinson's disease, HucMSC-Exos have demonstrated the ability to cross the blood-brain barrier and reach the substantia nigra, where they exert neuroprotective effects by inducing autophagy and inhibiting the apoptosis of dopaminergic neurons. Preclinical research suggests their therapeutic potential across a wide spectrum of conditions, including type 1 diabetes, liver fibrosis, acute kidney injury, wound healing, and myocardial infarction, primarily through anti-inflammatory and regenerative mechanisms.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hucMSC-derived exosomes.